stoxline Quote Chart Rank Option Currency Glossary
  
Rubius Therapeutics, Inc. (RUBY)
0.057  0.002 (2.7%)    12-29 15:49
Open: 0.0555
High: 0.057
Volume: 755,858
  
Pre. Close: 0.0555
Low: 0.055
Market Cap: 5(M)
Technical analysis
2023-05-19 4:48:08 PM
Short term     
Mid term     
Targets 6-month :  0.02 1-year :  0.03
Resists First :  0.02 Second :  0.02
Pivot price 0.02
Supports First :  0.01 Second :  0.01
MAs MA(5) :  0.01 MA(20) :  0.02
MA(100) :  0.1 MA(250) :  0.4
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  28.9 D(3) :  25.2
RSI RSI(14): 33.2
52-week High :  1.57 Low :  0.01
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ RUBY ] has closed above bottom band by 6.4%. Bollinger Bands are 93.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 38 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.02 - 0.02 0.02 - 0.02
Low: 0.02 - 0.02 0.02 - 0.02
Close: 0.02 - 0.02 0.02 - 0.02
Company Description

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Headline News

Wed, 28 Feb 2024
Rubius Therapeutics Cuts Almost 85% Of Its Workforce, Starts Looking For Strategic Alternatives - AOL

Fri, 29 Dec 2023
RUBIUS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer ... - Marketscreener.com

Wed, 22 Feb 2023
RUBY stock jumps on plan for liquidation (NASDAQ:RUBY) - Seeking Alpha

Wed, 22 Feb 2023
Rubius Therapeutics Outlines Dissolution Plan, After Unsuccessful Attempt On Alternatives - Yahoo Finance

Wed, 22 Feb 2023
Once high-flying Rubius to shut down. Its flameout is a lesson for biotech - STAT

Tue, 14 Feb 2023
Why Is Rubius Therapeutics (RUBY) Stock Up 35% Today? - InvestorPlace

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 90 (M)
Shares Float 47 (M)
Held by Insiders 5.5 (%)
Held by Institutions 53.6 (%)
Shares Short 1,530 (K)
Shares Short P.Month 2,480 (K)
Stock Financials
EPS -2.08
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.17
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -46.7 %
Return on Equity (ttm) -185.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.34
Qtrly Earnings Growth 0 %
Operating Cash Flow -150 (M)
Levered Free Cash Flow -85 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0.1
Price to Sales 0
Price to Cash Flow -0.02
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android